Histrelin
Supprelin (histrelin) is a protein pharmaceutical. Histrelin was first approved as Supprelin on 1991-12-24. It is used to treat precocious puberty in the USA. It is known to target gonadotropin-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Supprelin (discontinued: Vantas)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Histrelin acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUPPRELIN LA | Endo | N-022058 RX | 2007-05-03 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| supprelin | New Drug Application | 2019-12-12 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Histrelin Acetate, Supprelin La, Endo Pharm | |||
| 8062652 | 2026-06-16 | U-1197 | |
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | 1 | — | — | 2 | 4 |
| Allergic rhinitis | D065631 | J30.9 | 2 | 1 | — | — | 2 | 4 | |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 2 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | 1 | — | — | — | 1 | |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | 3 | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 12 | 12 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | — | 2 | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | — | 1 | 1 | |
| Skin diseases | D012871 | L00-L99 | — | — | — | — | 1 | 1 | |
| Acute pain | D059787 | R52 | — | — | — | — | 1 | 1 | |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | — | — | 1 | 1 | |
| Diet therapy | D004035 | — | — | — | — | 1 | 1 | ||
| Chronic urticaria | D000080223 | L50.8 | — | — | — | — | 1 | 1 | |
| Bronchial diseases | D001982 | — | — | — | — | 1 | 1 | ||
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HISTRELIN |
| INN | histrelin |
| Description | Histrelin is an oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. It has a role as an antineoplastic agent and a gonadotropin releasing hormone agonist. |
| Classification | Protein |
| Drug class | prehormones or hormone-release stimulating peptides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1 |
Identifiers
| PDB | — |
| CAS-ID | 76712-82-8 |
| RxCUI | 50975 |
| ChEMBL ID | CHEMBL1201255 |
| ChEBI ID | 5739 |
| PubChem CID | 25077993 |
| DrugBank | DB06788 |
| UNII ID | H50H3S3W74 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 335 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
590 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more